PFI financials
This article was originally published in The Tan Sheet
Executive Summary
Pharmaceutical Formulations first quarter net sales reached $18.4 mil., a 13.2% increase over the comparable period last year, attributable to the addition of sales from Konsyl Pharmaceuticals, acquired roughly one year ago. Excluding Konsyl, sales fell 2.2% to $15.9 mil., reflecting "increased price competition in the private label over-the-counter market, higher retailer rebate programs and an abrupt decline in the overall cough/cold market in the first quarter 2004." Edison, N.J. firm incurred a net loss of $1.4 mil in the quarter, compared to a $548,000 deficit the prior year, due to lower private label sales and higher selling, general and administrative expenses, company says...
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.